News Releases

RNS Number : 6380L MaxCyte, Inc. 14 September 2021         MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections   GAITHERSBURG, MD , September 13, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell

GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 8949K MaxCyte, Inc. 06 September 2021           MaxCyte, Inc. (" MaxCyte " or the "Company")     Issue of Equity   Increase to Block Listing   Block Listing Return   and   Total Voting Rights       GAITHERSBURG, MD , September 6, 2021   - MaxCyte, Inc.

RNS Number : 5833K MaxCyte, Inc. 02 September 2021   MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021   GAITHERSBURG, MD , September 02, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S.

RNS Number : 0791I MaxCyte, Inc. 10 August 2021       MaxCyte, Inc. (" MaxCyte " or the "Company")   Grant of Options                                                 Gaithersburg, Maryland - 10 August 2021 :   MaxCyte  (Nasdaq: MXCT) (LSE: MXCT, MXCN) , a leading provider of cell-engineering

Agreement represents MaxCyte's 14th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in conjunction with the development of its hypoimmune cell therapy programs GAITHERSBURG, Md. , Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc.

RNS Number : 9261H MaxCyte, Inc. 09 August 2021         MaxCyte Signs Clinical and Commercial License with Sana Biotechnology   Agreement represents MaxCyte's 14 th strategic platform license (SPL)    Sana will use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform in conjunction

RNS Number : 7572H MaxCyte, Inc. 05 August 2021         Amendments to Bylaws   GAITHERSBURG, MD , August 5, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company "), a leading provider of cell-engineering platform technologies, announces that it has filed amended

RNS Number : 4604H MaxCyte, Inc. 03 August 2021           MaxCyte Announces Closing of Offering and Resulting Total Voting Rights   This announcement contains inside information   GAITHERSBURG, MD , August 3, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company